Show simple item record

dc.contributor.authorBerges, A
dc.contributor.authorCheung, A
dc.contributor.authorPierce, A
dc.contributor.authorDean, E
dc.contributor.authorFelicetti, B
dc.contributor.authorStandifer, N
dc.contributor.authorSmith, S
dc.contributor.authorYates, J
dc.contributor.authorLau, A
dc.contributor.authorStephens, C
dc.contributor.authorKrebs, Matthew G
dc.contributor.authorHarrington, K
dc.contributor.authorHollingsworth, S
dc.date.accessioned2019-09-11T09:09:18Z
dc.date.available2019-09-11T09:09:18Z
dc.date.issued2018en
dc.identifier.citationBerges A, Cheung SYA, Pierce AJ, Dean E, Felicetti B, Standifer N, et al. PK-biomarker-safety modelling aids choice of recommended phase II dose and schedule for AZD6738 (ATR inhibitor). Cancer Res. 2018;78(13).en
dc.identifier.doi10.1158/1538-7445.AM2018-CT118en
dc.identifier.urihttp://hdl.handle.net/10541/622035
dc.language.isoenen
dc.relation.urlhttps://dx.doi.org/10.1158/1538-7445.AM2018-CT118en
dc.titlePK-biomarker-safety modelling aids choice of recommended phase II dose and schedule for AZD6738 (ATR inhibitor)en
dc.typeMeetings and Proceedingsen
dc.contributor.departmentQuantitative Clinical Pharmacology, Early Clinical Development, IMED Biotech Unit, AstraZeneca, Cambridgeen
dc.identifier.journalCancer Researchen
dc.description.noteen]


This item appears in the following Collection(s)

Show simple item record